Study · Randomized controlled trial · n = 13 · 2004

14 results

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O

Diabetes1 May 2004Cited by 328 (Europe PMC)

PMID15111485DOI10.2337/diabetes.53.5.1187PepBankPUB-15111485

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, liraglutide significantly reduced the 24-h area under the curve for glucose versus placebo.
In plain wordsIn people with type 2 diabetes, liraglutide lowered blood sugar over 24 hours more than placebo.
Peptide
Liraglutide
Outcome
Decrease24-h glucose AUC
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
Liraglutide significantly reduced the 24-h area under the curve for glucose (P = 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148501
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, liraglutide significantly reduced the 24-h glucagon area under the curve versus placebo.
In plain wordsIn people with type 2 diabetes, liraglutide lowered glucagon over 24 hours more than placebo.
Peptide
Liraglutide
Outcome
Decrease24-h glucagon AUC
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
and glucagon (P = 0.04), whereas the area under the curve for circulating free fatty acids was unaltered.
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148502
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, the 24-h area under the curve for free fatty acids was unaltered by liraglutide.
In plain wordsIn people with type 2 diabetes, liraglutide did not change free fatty acids in the blood over 24 hours.
Peptide
Liraglutide
Outcome
No significant change24-h free fatty acid AUC
Study
n = 13
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
whereas the area under the curve for circulating free fatty acids was unaltered.
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148503
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, 24-h insulin secretion rates were unchanged with liraglutide, indicating a relative increase.
In plain wordsIn people with type 2 diabetes, insulin secretion over 24 hours did not change with liraglutide, although blood sugar fell.
Peptide
Liraglutide
Outcome
No significant change24-h insulin secretion rate
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
Twenty-four-hour insulin secretion rates as assessed by deconvolution of serum C-peptide concentrations were unchanged, indicating a relative increase.
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148504
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, gastric emptying was not influenced at the liraglutide dose used.
In plain wordsIn people with type 2 diabetes, liraglutide at this dose did not change how fast the stomach emptied.
Peptide
Liraglutide
Outcome
No significant changeGastric emptying
Study
n = 13
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
Gastric emptying was not influenced at the dose of liraglutide used.
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148505
06HumanRandomized controlled trialMechanism
In patients with type 2 diabetes, liraglutide decreased fasting endogenous glucose release.
In plain wordsIn people with type 2 diabetes, liraglutide reduced the sugar the body released while fasting.
Peptide
Liraglutide
Outcome
DecreaseFasting endogenous glucose release
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
Fasting endogenous glucose release was decreased (P = 0.04)
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148506
07HumanRandomized controlled trialMechanism
In patients with type 2 diabetes, liraglutide reduced glycogenolysis.
In plain wordsIn people with type 2 diabetes, liraglutide reduced the breakdown of stored sugar in the body.
Peptide
Liraglutide
Outcome
DecreaseGlycogenolysis
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
as a result of a reduced glycogenolysis (P = 0.01), whereas gluconeogenesis was unaltered.
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148507
08HumanRandomized controlled trialMechanism
In patients with type 2 diabetes, gluconeogenesis was unaltered by liraglutide.
In plain wordsIn people with type 2 diabetes, liraglutide did not change how much new sugar the body made.
Peptide
Liraglutide
Outcome
No significant changeGluconeogenesis
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
whereas gluconeogenesis was unaltered.
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148508
09HumanRandomized controlled trialMechanism
In patients with type 2 diabetes, liraglutide markedly increased the first-phase insulin response during hyperglycemia.
In plain wordsIn people with type 2 diabetes, liraglutide strongly increased the early insulin response to high blood sugar.
Peptide
Liraglutide
Outcome
IncreaseFirst-phase insulin response
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
First-phase insulin response and the insulin response to an arginine stimulation test with the presence of hyperglycemia were markedly increased (P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148509
10HumanRandomized controlled trialMechanism
In patients with type 2 diabetes, liraglutide markedly increased the insulin response to an arginine stimulation test with hyperglycemia.
In plain wordsIn people with type 2 diabetes, liraglutide strongly increased the insulin response to an arginine test.
Peptide
Liraglutide
Outcome
IncreaseInsulin response to arginine stimulation during hyperglycemia
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
First-phase insulin response and the insulin response to an arginine stimulation test with the presence of hyperglycemia were markedly increased (P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148510
11HumanRandomized controlled trialMechanism
In patients with type 2 diabetes, the proinsulin/insulin ratio fell with liraglutide.
In plain wordsIn people with type 2 diabetes, the proinsulin to insulin ratio fell with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseProinsulin/insulin ratio
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
whereas the proinsulin/insulin ratio fell (P = 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148511
12HumanRandomized controlled trialMechanism
In patients with type 2 diabetes, the disposition index almost doubled during liraglutide treatment.
In plain wordsIn people with type 2 diabetes, a measure of insulin cell function almost doubled with liraglutide.
Peptide
Liraglutide
Outcome
IncreaseDisposition index
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
The disposition index (peak insulin concentration after intravenous bolus of glucose multiplied by insulin sensitivity as assessed by homeostasis model assessment) almost doubled during liraglutide treatment (P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148512
13HumanRandomized controlled trialMechanism
In patients with type 2 diabetes, the glucagon response during hyperglycemia was reduced with liraglutide.
In plain wordsIn people with type 2 diabetes, liraglutide reduced the glucagon response to high blood sugar.
Peptide
Liraglutide
Outcome
DecreaseGlucagon response during hyperglycemia
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
Both during hyperglycemia per se and after arginine exposure, the glucagon responses were reduced during liraglutide administration (P < 0.01 and P = 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148513
14HumanRandomized controlled trialMechanism
In patients with type 2 diabetes, the glucagon response after arginine exposure was reduced with liraglutide.
In plain wordsIn people with type 2 diabetes, liraglutide reduced the glucagon response to an arginine test.
Peptide
Liraglutide
Outcome
DecreaseGlucagon response after arginine exposure
Study
n = 13
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
6 micro g/kg once daily · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
Both during hyperglycemia per se and after arginine exposure, the glucagon responses were reduced during liraglutide administration (P < 0.01 and P = 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design.
Summary · context
Liraglutide (6 micro g/kg) was administered subcutaneously once daily.
Report a problemFND-1511148514

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 3 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03819790

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

LMC Diabetes & Endocrinology Ltd.n = 1192 Oct 2018 to 19 Nov 2019

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 25 Feb 2021

CompletedPhase 4NCT02488057

Improving Beta Cell Function in Mexican American Women With Prediabetes

Ohio State Universityn = 360May 2016 to Mar 2019

Pre-Diabetes

Trial page ClinicalTrials.govUpdated 28 Aug 2019

CompletedPhase 2NCT01508923

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 17May 2001 to Feb 2002

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 24 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.